Edesa Biotech Reports Increased Net Loss and Rising R&D Expenses for Third Quarter 2026

Edesa Biotech, Inc. reported significant financial results for the third quarter and nine months ended June 30, 2026, reflecting a net loss of $5.4 million, or $0.60 per share, compared to a net loss of $1.7 million, or $0.25 per share, for the same period in 2025. For the nine months, the company recorded a net loss of $11.9 million, or $1.40 per share, up from a loss of $5.0 million, or $0.95 per share, in the prior year. Total operating expenses increased to $5.5 million for the quarter and $12.2 million for the nine months, driven primarily by a substantial rise in research and development (R&D) costs, which surged to $4.0 million and $7.8 million, respectively, due to preparations for clinical studies and manufacturing activities.

The company’s total assets decreased to $12.7 million as of June 30, 2026, down from $13.5 million at the end of the previous fiscal year. Current liabilities rose sharply to $3.9 million, compared to $1.1 million in the prior year, largely due to increased accounts payable and accrued liabilities. Shareholders' equity also declined to $8.8 million from $12.5 million, reflecting the ongoing losses and increased share issuance. Edesa ended the period with $10.3 million in cash and cash equivalents, a decrease from $10.8 million as of September 30, 2025.

Strategically, Edesa has been active in financing activities, raising approximately $3.5 million through a private placement of common shares in June 2026. The company also reported a decrease in grant income from the Canadian government’s Strategic Response Fund, which contributed $0.1 million in the latest quarter, down from $0.2 million in the same quarter last year. The company is focused on advancing its clinical pipeline, particularly the Phase 2 study of EB06 for vitiligo, and has initiated preparations for manufacturing scale-up for its paridiprubart program.

Operationally, Edesa's R&D expenses reflect a commitment to its clinical programs, with significant investments in the EB06 and paridiprubart candidates. The company is also exploring additional funding avenues to support its operations, including potential collaborations and licensing agreements. Edesa's management has indicated that while the current cash position is sufficient for the near term, additional financing will be necessary to continue its development efforts and meet operational obligations. The company remains focused on addressing unmet medical needs in inflammatory and immune-related diseases, with plans to expand its product pipeline and geographic reach in the future.